BridgeBio Pharma, Inc.
BBIONasdaqCIK 1743881HealthcareFiscal year ends Dec 31
All transactions: 7
Non-derivative transactions reported on Forms 4, newest first. Purchases and sales (codes P and S) are open-market trades; the other codes are grants, exercises, withholding and gifts. The reported price is as stated on the form, not a market price.
What these mean: insiders, Form 4, transaction codes, Rule 10b5-1 plans.
| Date | Insider | Transaction | Shares | Reported price | Value | Filing |
|---|---|---|---|---|---|---|
| 2025-05-12 | KKR Genetic Disorder L.P.10% owner | Sale | 6,000,000 | $34.20 | $205.2m | Form 4 |
| 2025-03-05 | KKR Genetic Disorder L.P.10% owner | Sale | 6,000,000 | $32.96 | $197.8m | Form 4 |
| 2024-09-13 | KKR Genetic Disorder L.P.10% owner | Sale | 5,800,000 | $25.75 | $149.3m | Form 4 |
| 2021-02-17 | KKR Genetic Disorder L.P.10% owner | Sale | 3,450,000 | $60.4688 | $208.6m | Form 4 |
| 2020-05-28 | KKR Genetic Disorder L.P.10% owner | Sale | 2,389,690 | $33.39 | $79.8m | Form 4 |
| 2019-07-01 | KKR Genetic Disorder L.P.10% owner | Purchase | 2,647,100 | $17.00 | $45.0m | Form 4 |
| 2019-07-01 | KKR Genetic Disorder L.P.10% owner | Conversion | 34,253,561 | not reported | not reported | Form 4 |
Source: SEC EDGAR, Forms 4. Last ingested by Listed: Oct 29, 2026, 19:20 ET. Listed shows no prices and gives no investment advice.